Overview

PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purposed of the study is to evaluate the pharmacokinetics (PK) response of continuous subcutaneous (SQ) infusion of cenderitide, as compared with a single SQ bolus.
Phase:
Phase 1
Details
Lead Sponsor:
Nile Therapeutics
Collaborator:
Integrium